Johnson & Johnson Q2 2026 Earnings: Pharma Strength Offsets STELARA Headwind, Guidance Raised

Johnson & Johnson (JNJ) reported $25.3 billion in Q2 2026 quarterly sales, a 5.6% increase on an operational basis year over year. The reported figure carries a significant asterisk: biosimilar competition against STELARA, the company's flagship immunology product, created a 460 basis point drag on reported growth. Strip out that headwind, and the underlying portfolio expanded at a double-digit rate, a distinction management cited directly when announcing a full-year guidance raise.

Earnings and the Guidance Raise

Net earnings for the quarter reached $5.5 billion. GAAP diluted EPS came in at $2.27; adjusted EPS rose nearly 5% year over year to $2.90. Both metrics reflect a business absorbing a known patent-cliff dynamic while generating profitable growth through it.

Full-year operational sales growth guidance increased to a range of 6.5% to 7.1%, and full-year adjusted EPS guidance moved to $11.50 to $11.65. The revised outlook positions J&J on a trajectory toward a historic $100 billion in annual revenue, a milestone that would reflect a decade of portfolio transformation from diversified consumer goods conglomerate to focused pharma-and-medtech enterprise.

Oncology: DARZALEX Anchors, Newer Agents Accelerate

The Innovative Medicine segment's oncology franchise produced the clearest evidence of portfolio momentum. DARZALEX, J&J's multiple myeloma antibody and the segment's largest single product, generated over $4 billion in quarterly revenue, up nearly 18% year over year. The product's scale places it among the top-grossing oncology agents globally, and the growth rate at that revenue base is notable.

Newer hematology and oncology agents contributed sharper acceleration. CARVYKTI, a BCMA-targeted CAR-T therapy, grew 47.7% in the quarter. TECVAYLI, a bispecific antibody targeting BCMA and CD3, grew 56%. TALVEY, another bispecific targeting GPRC5D, grew 62.6%. These three products address earlier and later treatment lines in multiple myeloma, giving J&J a presence across the disease's full arc of care.

Clinical Data Reinforces Franchise Durability

Combination data from the TALVEY-DARZALEX regimen provided additional context for the franchise's long-term positioning. The data showed more than 80% of patients progression-free at two years, with overall survival reaching 89% at the same mark. For a disease where relapse rates have historically been high, those figures support a durable commercial platform rather than a cycle-dependent revenue peak.

Immunology: TREMFYA's Milestone Quarter and ICOTYDE's Launch

TREMFYA, J&J's IL-23 inhibitor approved across inflammatory bowel disease and plaque psoriasis, achieved its first $2 billion quarterly revenue figure, growing 71% year over year. The milestone reflects both the breadth of the underlying IBD indication and TREMFYA's competitive positioning against older TNF inhibitors and IL-12/23 agents.

Alongside TREMFYA, J&J launched ICOTYDE during the period. Adoption metrics point to rapid early uptake: more than 11,000 patients initiated therapy, drawing on more than 6,000 unique prescribers. Within 90 days of launch, more than half of commercial payers covered the treatment. A payer coverage ramp of that speed is unusual for a specialty biologic and signals broad perceived clinical differentiation from existing options.

MedTech: Behavioral Headwind, Not Structural Decline

The MedTech segment grew 3.6% in the quarter, trailing the Innovative Medicine division's pace. The Abiomed cardiovascular business, home to the Impella heart pump platform, was the primary drag. Physician adoption patterns shifted following the publication of a UK-based trial on Impella devices, and management addressed the data gap directly on the earnings call.

The UK study enrolled roughly 300 patients. J&J's own Impella evidence base covers more than 40,000 patients across a range of indications and acuity levels. The mismatch in statistical scale is significant, yet the smaller dataset influenced near-term physician behavior in certain cardiac surgery settings. The dynamic is behavioral rather than competitive: no alternative technology captured the cases that Abiomed lost in the period.

J&J's PROTECT IV trial, designed to produce a prospective randomized dataset addressing the uncertainty around Impella in high-risk procedures, is not expected to read out until 2027. That timeline means the Abiomed line faces several more quarters of headline-level softness before clinical trial data can reframe the physician-level narrative.

Portfolio Breadth and the Path to $100 Billion

J&J now operates 28 products or platforms each generating over $1 billion in annual revenue. That franchise count provides a natural offset mechanism: STELARA's biosimilar erosion, substantial at 460 basis points of reported growth headwind, was absorbed by double-digit expansion across the rest of the portfolio. The MedTech slowdown, concentrated in the Abiomed line, did not prevent a full-year guidance raise.

The guidance raise to a 6.5% to 7.1% operational growth range reflects management's confidence in second-half execution across both segments. With ICOTYDE ramping, TREMFYA past its $2 billion quarterly threshold, and oncology agents growing well above 40% per year, the drivers of the second-half acceleration are visible in the current portfolio mix. The combination of 28 established billion-dollar franchises and several high-growth newer launches gives the company multiple vectors for hitting the raised outlook.

For a full breakdown of J&J's Q2 2026 results and management commentary, listen to the Johnson & Johnson Q2 2026 earnings podcast at /podcasts/JNJ_Q2_2026. Additional large-cap pharma and medtech coverage is available in the healthcare sector episodes at /groups/healthcare.

• Q2 2026 sales: $25.3 billion, +5.6% operational growth
• STELARA biosimilar headwind: 460 basis points on reported growth
• Net earnings: $5.5 billion; GAAP diluted EPS $2.27; adjusted EPS $2.90 (+~5% year over year)
• Full-year guidance: 6.5%–7.1% operational growth; adjusted EPS $11.50–$11.65
• DARZALEX: over $4 billion quarterly revenue, up nearly 18%
• CARVYKTI +47.7%, TECVAYLI +56%, TALVEY +62.6% in Q2
• TREMFYA: first $2 billion quarter, +71%; ICOTYDE: 11,000+ patients, 6,000+ prescribers, majority of payers covering within 90 days
• MedTech growth: 3.6%; PROTECT IV trial readout expected 2027
• 28 products or platforms each generating over $1 billion in annual revenue